Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Lupin was founded in 1968 by Desh Bandhu Gupta,[10] who was a professor of chemistry at BITS-Pilani, Rajasthan. Gupta initially borrowed Rs. 5000 from his wife to fund the venture. Due to subsequent funding from the Central Bank of India, the company able to start their manufacturing facility for producing folic acid and iron tablets for the Indian government's mother and child health program. Later Lupin started manufacturing anti-tuberculosis (TB) drugs which at one point formed 36% of the company sales and was considered as the largest TB drugs manufacturer in the world.[11]

In 1988 Gupta founded the group's CSR arm, the Lupin Human Welfare & Research Foundation (LHWRF). This initiative was dedicated to sustainable rural development with the aim to uplift families living below the poverty line.[12] In 1999, Lupin joined the Indian Pharmaceutical Alliance as a founding member.[13][14]

In July 2015 the company announced its intention to acquire Gavis Pharmaceuticals and Novel Laboratories for $880 million.[15][16]

The founder, Desh Bandhu Gupta died in June 2017 and was subsequently replaced as chairman by his wife, Manju Deshbandhu Gupta.[17]

In October 2019, Lupin announced the Appointment of Sreeji Gopinatham as Chief Information Officer (CIO).[18]

In March 2019, the US FDA put several Lupin drug plants on notice for quality problems, and indicated it might not approve future Lupin drug applications.

In May 2023, Lupin entered into an agreement to buy the French pharmaceutical company Medisol.[19]